Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — MGC Pharmaceuticals — Non-Deal Roadshow (September 2015)
16 slides from Argent Biopharma's roadshow presentation, September 2015
Slide 1: Investment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation June Roadshow
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Erin Resources Limited (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any
Slide 3: Transaction Overview
Transaction Overview Erin Resources Limited has entered into a binding heads of agreement under which it has the exclusive option to acquire 100% of the issued capital in MGC Pharmaceuticals Ltd (MGC), a European based medical and cosmetic cannabis company Capital Structure − post MGC acquisition Or
Slide 4: Company Overview MGC Pharmaceuticals
Company Overview MGC MGC Pharmaceuticals Limited (MGC), is a medical and cosmetic cannabis company operations in Pharmaceuticals Slovenia, founders have significant technical and commercial experience in the medical and cosmetics Capitalising on “Israeli MC IP” cannabis industry – world leaders in t
Slide 5: Investment Highlights
Investment Highlights • Strategically positioned to exploit the rapidly growing demand for medical cannabis (worth US$2.7bn) and CBD in the cosmetic (cosmetic market globally estimated at US$270 b and $70 b in Europe in 2014) • Unique genetics from exclusive strain of Cannabis Sativa comprising very
Slide 6: MC Industry Leaders- Expertise and Experience
MC Industry Leaders- Expertise and Experience Nativ Segev Roby Zomer Yaron Blubshtin Co-Founder and Co-Founder and Director of Chief Agronomist / Managing Director Business Development Advisor Nativ Segev was the CEO of Roby Zomer brings a wealth of Yaron Blubshtin holds over 45 Israel’s second larg
Slide 7: Key Milestones
Key Milestones Secured licenses to grow, extract and import/export CBD resin in the EU - COMPLETED Initial €40,000,000 offtake agreement to supply CBD Resin - COMPLETED Joint Venture Agreement for cosmetics and medical products R&D - COMPLETED Launch of first MGC line of cosmetics products - H2 2015
Slide 8: Business Activity Pipeline and Timetable
Business Activity Pipeline and Timetable Register genetic Begin first First revenues bank in Slovenia cultivation and from off-take and the EU extraction agreement Q3 2015 H1 2016 H2 2016 H2 2015 H1 2016 Q1 2017 Establish Establish growing Apply for and growing protocols and obtain outdoor operation
Slide 9: Global Market Opportunity
Global Market Opportunity • Cannabinoids are legal in 23 U.S states and the MC market is estimated to be worth USD$2.7 billion globally in 2014 and US$10 billion by 2019 • In Canada the market for medical cannabis is expected to grow significantly, from $144m in 2014 • Common diseases for which Cann
Slide 10: CBD Global Market − Mainstream Cosmetics
CBD Global Market − Mainstream Cosmetics • In 2013 the cosmetics industry was worth US$270 billion - over 100 times that of the medical marijuana industry for 2014. • CBD resins used increasingly as base product in the cosmetics industry • The skin care market is estimated to account for 37% of the
Slide 11: Cannabidiol (CBD) – Global Potential
Cannabidiol (CBD) – Global Potential • Found only in cannabis plants, Cannabidiol (CBD) is the non- psychoactive ingredient • Impacts pathways in the body, which control pain and support the immune system, thereby delivering significant medicinal benefits in the treatment of chronic pain • It has a
Slide 12: High CBD Cannabis Sativa
High CBD Cannabis Sativa Wider Market Legality CBD Cannabis Sativa legally produced - under Cannabis license Legal in 23 states in the U.S 12
Slide 13: CBD Market Expected to Grow
CBD Market Expected to Grow US$ millions Canada U.S Europe Canada 10.2 10 CAGR +30% 6.8 U.S CAGR +45% Europe 2.3 CAGR +10% 0.6 0.2 E2014 E2018 13
Slide 14: Strategic and Focused Business Plan: Licensing
Strategic and Focused Business Plan Licensing Register Good License strains and Register High CBD Manufacturing guidelines to growing strains in Europe Practice (GMP) operations in Europe First revenues via off- Growing Establish Sativa take agreements of Apply for additional Growing operation in fi
Slide 15: Investment Summary
Investment Summary • Strategically positioned to exploit the rapidly growing demand for medical cannabis (worth US$2.7bn) and CBD in the cosmetic (cosmetic market globally estimated at US$270 b and $70 b in Europe in 2014) • Unique genetics from exclusive strain- high CBD levels (>13%) yielding high
Slide 16: Contact Information
Contact Information Media Enquiries Asher Moses Director Media and Capital Partners +61 438 008 616 Asher.moses@mcpartners.com.au Erin Resources Limited Brett Mitchell Executive Director +61 8 9389 2000 info@erinresources.com.au 16
MGC Pharmaceuticals — Non-Deal Roadshow (September 2015) on 6ix